Efficacy and Safety of Aflibercept as Mono-therapy in Treat and Extend Regimen for DME Patients in Taiwan
Status:
Completed
Trial end date:
2017-11-16
Target enrollment:
Participant gender:
Summary
Phase IIIb, multicenter, open-label, prospective, interventional study to assess the
potential benefit of Aflibercept treatment administered IVT at a dosage of 2 mg with five
monthly loading doses and then treat and extend over 48 weeks, with the primary endpoint as
BCVA assessed at Week 52.
Phase:
Phase 3
Details
Lead Sponsor:
Taipei Veterans General Hospital, Taiwan
Collaborators:
Chang Gung Memorial Hospital Kaohsiung Veterans General Hospital. National Taiwan University Hospital